Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Eric Gottenberg

Showing results (171-180 of 311) with videos related to

Pageof 32
Sort By:
QJM : Monthly Journal of the Association of Physicians|January 11, 2017
Idiosyncratic drug-induced neutropenia & agranulocytosisEmmanuel Andrès, Rachel Mourot-Cottet, Frédéric Maloisel, et al.
Drugs - Real World Outcomes|October 18, 2016
Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 CasesRachel Mourot-Cottet, Frédéric Maloisel, François Séverac, et al.
The Journal of Rheumatology|August 17, 2012
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of RheumatologyDaniel Wendling, Maxime Dougados, Francis Berenbaum, et al.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
European Journal of Internal Medicine|November 9, 2020
Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF studyMaria Betânia Ferreira, Tomás Fonseca, Rita Costa, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2006
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndromeJacques-Eric Gottenberg, Nicolas Cagnard, Carlo Lucchesi, et al.
American Journal of Hematology|December 17, 2017
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adultsAlexandra Serris, Zahir Amoura, Florence Canouï-Poitrine, et al.
Annals of the Rheumatic Diseases|May 7, 2016
Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studiesRaphaèle Seror, Petra Meiners, Gabriel Baron, et al.
Rheumatology (Oxford, England)|September 29, 2017
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATEJacques Morel, Arnaud Constantin, Gabriel Baron, et al.
Journal of Autoimmunity|December 3, 2014
B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosisAntoine François, Aurélie Gombault, Bérengère Villeret, et al.
Pageof 32

Showing results (171-180 of 311) with videos related to

Sort By:
Pageof 32
QJM : Monthly Journal of the Association of Physicians|January 11, 2017
Idiosyncratic drug-induced neutropenia & agranulocytosisEmmanuel Andrès, Rachel Mourot-Cottet, Frédéric Maloisel, et al.
Drugs - Real World Outcomes|October 18, 2016
Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 CasesRachel Mourot-Cottet, Frédéric Maloisel, François Séverac, et al.
The Journal of Rheumatology|August 17, 2012
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of RheumatologyDaniel Wendling, Maxime Dougados, Francis Berenbaum, et al.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
European Journal of Internal Medicine|November 9, 2020
Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF studyMaria Betânia Ferreira, Tomás Fonseca, Rita Costa, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2006
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndromeJacques-Eric Gottenberg, Nicolas Cagnard, Carlo Lucchesi, et al.
American Journal of Hematology|December 17, 2017
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adultsAlexandra Serris, Zahir Amoura, Florence Canouï-Poitrine, et al.
Annals of the Rheumatic Diseases|May 7, 2016
Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studiesRaphaèle Seror, Petra Meiners, Gabriel Baron, et al.
Rheumatology (Oxford, England)|September 29, 2017
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATEJacques Morel, Arnaud Constantin, Gabriel Baron, et al.
Journal of Autoimmunity|December 3, 2014
B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosisAntoine François, Aurélie Gombault, Bérengère Villeret, et al.
Pageof 32